Navigation Links
Amarin Secures Global Intellectual Property Rights for Lipid Programs
Date:3/3/2008

ce as a sponsor of such research and development to bring much needed treatments to important medical conditions."

About Amarin

Amarin is committed to improving the lives of patients suffering from central nervous system (CNS) and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation.

Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively.

Disclosure Notice

The information contained in this document is as of March 3, 2008. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking statements about Amarin's financial condition, results of operations, business prospects and products in research that involve substantial risks and uncertainties. You can identify these statements by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe" and other words and terms of similar meaning in conn
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Amarin Appoints Dr. William Mason as Lead Independent Director
2. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
3. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
4. Amarin Signs Agreement to Acquire Ester Neurosciences
5. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
6. Amarin Announces Initiation of Cardiovascular Development Strategy
7. Amarin to Present at 4th Annual Bio Investor Forum
8. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
9. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
10. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
11. Taligen Therapeutics Secures Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Cempra, ... on developing differentiated antibiotics to meet critical medical ... announced that it presented data at the American ... Philadelphia demonstrating the antibacterial and ... Cempra,s prior Phase 2 clinical trial in outpatients ...
(Date:5/20/2013)... 20, 2013 Recognizing exciting and ... members to its 2013 Class of Young Professors. ... will provide this outstanding international group with more ... basic science to meet global challenges.     , The ... promising young and untenured research faculty working in ...
(Date:5/19/2013)... Switzerland’s MS Tûranor PlanetSolar , the ... record for a transatlantic crossing by a solar electric ... 25, 2013, the solar powered boat sailed 2,867miles (5,310 ... of 5.3 knots before reaching Marigot, St. Martin, in ... first-of-its-kind catamaran completed this year’s passage across the Atlantic ...
(Date:5/17/2013)... rejection occurs when the transplant recipient,s immune system identifies ... It was previously thought that T cells, the immune ... molecules known as chemokines in order to migrate to ... Journal of Clinical Investigation , Fadi Lakkis and colleagues ... that chemokine stimulation of T cells is not required ...
Breaking Biology Technology:Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6
... LEUVEN, Belgium, August 27 ThromboGenics NV,(Euronext Brussels: THR), a ... for eye disease, vascular disease,and cancer, is today issuing a ... period ending 30 June, 2009. , ... which,are key to its aim of becoming a profitable, integrated ...
... Massachusetts and CHEADLE, England, August 27 ,Cardea Technology, ... and configure their software tools for Vertebral Fracture,Assessment, ... on bone,densitometers, to exchange information and create reports ... Optasia Medical Ltd. has developed SpineAnalyzer(TM), a ...
... , , ATLANTA, Aug. 27 ... million extension of its Series C financing which was originally completed in ... $5 million in Series C preferred stock received warrants for an additional ... have up to 30 days from the delivery of Phase III top-line ...
Cached Biology Technology:ThromboGenics NV Announces Business Update and Half Year Results 2009 2ThromboGenics NV Announces Business Update and Half Year Results 2009 3ThromboGenics NV Announces Business Update and Half Year Results 2009 4ThromboGenics NV Announces Business Update and Half Year Results 2009 5ThromboGenics NV Announces Business Update and Half Year Results 2009 6ThromboGenics NV Announces Business Update and Half Year Results 2009 7ThromboGenics NV Announces Business Update and Half Year Results 2009 8ThromboGenics NV Announces Business Update and Half Year Results 2009 9ThromboGenics NV Announces Business Update and Half Year Results 2009 10ThromboGenics NV Announces Business Update and Half Year Results 2009 11ThromboGenics NV Announces Business Update and Half Year Results 2009 12ThromboGenics NV Announces Business Update and Half Year Results 2009 13ThromboGenics NV Announces Business Update and Half Year Results 2009 14ThromboGenics NV Announces Business Update and Half Year Results 2009 15Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools 2Alimera Sciences Closes $5 Million in Extended Series C Financing 2
(Date:5/18/2013)... presented at Digestive Disease Week (DDW) explores new ... lifestyle. , Individuals suffering from Crohn,s disease ... and poor quality of life. These symptoms can ... randomized, double blind, placebo-controlled study found for the ... significant relief of these symptoms. , "Our ...
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... The Federation of American Societies for Experimental Biology ... Institutes of Health (NIH) funding trends highlighting the devastating ... critical research. The FASEB analysis follows a May 15th ... MD, PhD, who testified that the $1.6 billion cut ... is "having a substantial impact on the scientific community." ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3First Atlanta Science Festival set for 2014 2
... A University of Leicester archaeologist has discovered a ... Staffordshire - believed to be the earliest archaeological evidence ... As reported in Post-Medieval Archaeology (volume 44/1) ... significance of the find is in the insights it ...
... your wedge may not help much, but mixing in longer ... studies have shown that variable practice improves the brain,s memory ... task. Cognitive neuroscientists at USC and UCLA describe the neural ... Nature Neuroscience . The researchers split 59 volunteers ...
... for regulating viruses that has worked its way into ... adult and fetal hemoglobin production, Medical College of Georgia ... to more targeted therapies for sickle cell patients whose ... throughout the body. Fetal hemoglobin, on the other ...
Cached Biology News:Archaeology find sheds new light on family pets 2Why (smart) practice makes perfect 2Modulator of fetal hemoglobin switch may target sickle cell disease 2Modulator of fetal hemoglobin switch may target sickle cell disease 3
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
GOAT ANTI HUMAN PSA (ISOFORM 1)...
... Immunogen: Synthetic peptide derived from the N-terminal ... ZO-1. Specificity: Specific for the N-terminus ... Reactivity: Human Dog Rat Mouse (positive controls: ... mouse liver heart blood vessel and brain ...
p-Raf-1 (Ser 338/Tyr 341)-R...
Biology Products: